VSTM2A Fusion

CI-VAR-00001354Explore in graph →CIViC 4343

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioblastoma1
EGFR::VSTM2A Fusion	Bevacizumab/Lomustine Regimen	Predictive	B	Supports Sensitivity Response	2	submitted	EID11101 EGFR::VSTM2A was identified by RNA-seq in tumor sample derived from 1/78 recurrent glioblastoma patients who benefited from combined beva/CCNU (bevacizumab in combination with lomustine) in the BELOB … (full text at CIViC) PMID 26762204 · Erdem-Eraslan et al., 2016 · Open in CIViC	civic
Lung Adenocarcinoma1
EGFR::VSTM2A Fusion	(oncogenic)	Oncogenic	E	Supports Oncogenicity	1	submitted	EID11103 Using NGS, genomic profiling from tumor/plasma biopsies from 17,442 Chinese lung cancer patients was performed. EGFR::VSTM2A reported in 2/1053 recurrent kinase fusions in lung cancer (NSCLC, adenocar… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

IDH-wildtype Glioblastoma1unmapped disease
EGFR::VSTM2A Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	1	submitted	EID11102 170 cases of IDH-wildtype GBM were screened using whole genome SNP arrays for chromothipsis. 66 cases of 170 demonstrated chromothripsis, of which 52 had adequate RNA available for RNA sequencing. RNA… (full text at CIViC) PMID 33074125 · Ah-Pine et al., 2021 · Open in CIViC	civic